The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
The US Food and Drug Administration (FDA) has granted Fast Track Designation to OPN-6602, an oral small-molecule EP300/CBP inhibitor, for patients with relapsed or refractory multiple
As we approach the end of the first quarter of 2026, I am pleased to share a brief update on the exceptional successes of the SOHO Ambassador program thus far this year.
The award recognizes an individual’s achievements and contributions in any aspect of blood cancer research.
SOHO will hold an exclusive session titled, “Practical Strategies for Optimizing Outcomes in MDS and AML,” starting at 3 pm on Tuesday, September 8, 2026, at the George R. Brown Convention Center in Houston, Texas, ahead of the SOHO 2026 Annual Meeting. The session will be chaired by Guillermo Garcia-Manero, MD, of the University of Texas MD Anderson Cancer Center.
Dr. Iftikhar is the SOHO Ambassador to Pakistan and a consultant clinical hematologist and hematopoietic stem cell transplantation physician at Armed Forces Bone Marrow Transplant Centre in Rawalpindi, Pakistan.
To access the SOHO Career Center click the following link.
